全文获取类型
收费全文 | 3921篇 |
免费 | 251篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 88篇 |
妇产科学 | 43篇 |
基础医学 | 316篇 |
口腔科学 | 167篇 |
临床医学 | 506篇 |
内科学 | 561篇 |
皮肤病学 | 82篇 |
神经病学 | 243篇 |
特种医学 | 127篇 |
外科学 | 455篇 |
综合类 | 421篇 |
预防医学 | 345篇 |
眼科学 | 191篇 |
药学 | 337篇 |
中国医学 | 34篇 |
肿瘤学 | 257篇 |
出版年
2023年 | 23篇 |
2022年 | 14篇 |
2021年 | 65篇 |
2020年 | 62篇 |
2019年 | 82篇 |
2018年 | 117篇 |
2017年 | 97篇 |
2016年 | 77篇 |
2015年 | 240篇 |
2014年 | 306篇 |
2013年 | 269篇 |
2012年 | 260篇 |
2011年 | 399篇 |
2010年 | 178篇 |
2009年 | 212篇 |
2008年 | 204篇 |
2007年 | 284篇 |
2006年 | 234篇 |
2005年 | 137篇 |
2004年 | 146篇 |
2003年 | 106篇 |
2002年 | 74篇 |
2001年 | 60篇 |
2000年 | 44篇 |
1999年 | 44篇 |
1998年 | 25篇 |
1997年 | 34篇 |
1996年 | 31篇 |
1995年 | 29篇 |
1994年 | 24篇 |
1993年 | 29篇 |
1992年 | 29篇 |
1991年 | 35篇 |
1990年 | 25篇 |
1989年 | 24篇 |
1988年 | 36篇 |
1987年 | 28篇 |
1986年 | 24篇 |
1985年 | 11篇 |
1984年 | 9篇 |
1983年 | 9篇 |
1982年 | 11篇 |
1981年 | 9篇 |
1980年 | 6篇 |
1979年 | 11篇 |
1977年 | 4篇 |
1976年 | 6篇 |
1975年 | 8篇 |
1974年 | 4篇 |
1968年 | 3篇 |
排序方式: 共有4218条查询结果,搜索用时 15 毫秒
1.
Ng Sean Ming Sheng Low Rebecca Hoskin Annette K. Rousselot Andres Gunasekeran Dinesh Visva Natarajan Sundaram Sundar Gangadhara Chee Caroline Ka Lin Mishra Chitaranjan Sen Parveen Pradhan Eli Irawati Yunia Kamalden Tengku Ain Shah Mehul Yan Hua Woreta Fasika A. Subramanian Prem S. Kuhn Ferenc Watson Stephanie L. Agrawal Rupesh 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(4):1055-1067
Graefe's Archive for Clinical and Experimental Ophthalmology - Ophthalmic trauma is a leading cause of preventable monocular blindness worldwide. The prevalence of ophthalmic trauma varies... 相似文献
2.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
3.
4.
Colorectal Cancer in Brunei Darussalam: An Overview and Rationale for National Screening Programme 下载免费PDF全文
Mei Ann LimVui Heng ChongSok King OngYa Chee Lim 《Asian Pacific journal of cancer prevention》2019,20(12):3571-3580
Colorectal cancer (CRC) is the third most common cancer worldwide after lung and breast cancers, and ranks second in terms of cancer mortality globally. Brunei Darussalam reports high incidence of CRC in the Southeast Asian region and has no formal national screening programme for CRC. Screening for CRC in Brunei Darussalam is offered in an opportunistic fashion for individuals with average or above average risks for CRC, that is, the individual has a positive family history of CRC or neoplasms and is more than 50 years old. Opportunistic screening is widely practiced but this is not standardised. The Ministry of Health in Brunei Darussalam is currently in the process of implementing a CRC screening programme as part of a larger national health screening based on the increasing incidence of non-communicable diseases (NCDs). This review article assesses the situation of CRC in Brunei Darussalam from the 1980s to present day, including incidence of CRC in different age groups, ethnicities and genders; relevant non-modifiable and modifiable risk factors of CRC in Brunei Darussalam setting; and common CRC screening techniques used in Brunei Darussalam as well as other Asia-Pacific countries. The review also discusses the merits of a national CRC screening programme. With the increasing incidence of CRC worldwide and in Brunei Darussalam, national screening for CRC in Brunei Darussalam is an important strategy to lower morbidity and mortality rates. A review of the progress and outcome of the national screening programme will be available a few years after rollout. 相似文献
5.
6.
7.
Min Dong Liang‐Nan Zeng Qinge Zhang Gabor S. Ungvari Chee H. Ng Helen F. K. Chiu Tian‐Mei Si Kang Sim Ajit Avasthi Sandeep Grover Mian‐Yoon Chong Kok‐Yoon Chee Shigenobu Kanba Min‐Soo Lee Shu‐Yu Yang Pichet Udomratn Roy A. Kallivayalil Andi J. Tanra Margarita M. Maramis Winston W. Shen Norman Sartorius Rathi Mahendran Chay‐Hoon Tan Naotaka Shinfuku Yu‐Tao Xiang 《Psychogeriatrics》2019,19(4):333-339
8.
Monica Tang Sallie-Anne Pearson Andrea L. Schaffer Craig R. Lewis Thomas John Robert J. Simes Chee Khoon Lee 《Journal of Geriatric Oncology》2021,12(6):930-936
ObjectivesOlder adults constitute the majority of patients with lung cancer. However, they are under-represented in clinical trials as eligibility criteria often restrict enrolment based on comorbidities that are common with aging. We aimed to describe comorbidities relating to trial exclusion criteria in older adults with lung cancer, determine the proportion that would typically be excluded from trials, and examine the impact on treatment uptake.Materials and MethodsWe conducted a population-based study of people aged ≥65 years diagnosed with metastatic lung cancer using linked data for clients of the Australian Government Department of Veterans' Affairs (2005–2015). We defined trial-typical patients based on the absence of comorbidities related to the following: inadequate organ (cardiac, renal, hepatic, marrow) function; cognitive dysfunction; poor performance status (PS); prior malignancy within 5 years. We report systemic therapy uptake within 3 months of diagnosis.ResultsOur study included 677 patients (median age 84). Over half (53.4%) were not trial-typical, with the most common reasons being poor PS (37.5%), cardiac disease (19.2%), and prior cancer (12.9%). Eighty-two (12.1%) received systemic therapy. Patients with poor PS, cardiac disease, and dementia had lower treatment uptake rates. However, there was no significant difference in treatment uptake between trial-typical and non-trial-typical patients (13.4 vs 11.0%).ConclusionMore than half of older adults with advanced lung cancer would be typically excluded from trial participation. Future clinical trials of older adults need to consider broader eligibility criteria to better reflect this population to gain the best evidence for their care. 相似文献
9.
10.
Jack Goldberg Tiffany Lee Jin-Ho Phark Winston Chee 《The Journal of prosthetic dentistry》2019,121(2):322-326